Avalo Therapeutics(AVTX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates • Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 • Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, PA AND ROCKVILLE, MD, May 13, 2024 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. "Over the past month we have made considera ...